查看购物车
  • Traditional Chinese
  • English
  • Japanese
精准诊断和精准医疗市场按类型、适应症、产品、最终用户和地区划分 - 预测至 2029 年
市场调查报告书
商品编码
1642243

精准诊断和精准医疗市场按类型、适应症、产品、最终用户和地区划分 - 预测至 2029 年

Precision Diagnostics & Medicine Market by Diagnostic Testing, Diagnostics Indication, Therapeutic Products, Indication - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 446 Pages | 订单完成后即时交付

价格

全球精准诊断和精准医疗市场规模预计将从 2024 年的 1,455.3 亿美元增至 2029 年的 2,466.6 亿美元，预测期内的复合年增长率为 11.1%。

人工智慧和机器学习等尖端技术的日益整合促进了精准医疗的发展，大型製药企业和诊断公司也透过合作和加大活性化来开发更好的精准医疗解决方案，这些因素共同支撑着市场的成长。此外，这些公司专注于开发多种疾病（包括神经退化性疾病疾病和自体免疫疾病）的精准治疗和诊断测试，凸显了精准医疗在医疗保健领域日益增长的重要性。此外，患者对自身健康的认识不断提高，推动了穿戴式医疗设备和直接面向消费者的精准诊断测试的采用，为该市场参与企业提供了成长机会。然而，精准医疗的高成本以及医疗巨量资料整合和管理所带来的挑战预计将抑制该市场的成长。

研究范围
调查年份 2022-2029
基准年 2023
预测期 2024-2029
考虑单位 金额（美元）
按细分市场 按类型、按适应症、按产品、按最终用户、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

2023 年，单株抗体部分在精准医疗市场中按产品类别达到最高成长率。加强合作开发先进单株抗体以及抗体工程技术的进步等因素促进了这一领域的成长。此外，与传统药物相比，这些治疗方法具有多种优势，例如特异性高、治疗方法低、疗效持续时间长，可用于治疗癌症、自体免疫疾病和感染疾病。支持该部分的成长。

在预测期内，医院和诊所最终用户在精准医疗市场中所录得的最高增长率。个人化治疗的需求不断增长，以及医院和诊所能够在受控环境中提供个人化治疗的能力等因素，导致该终端用户群体占据了较大的份额。此外，医院与製药和诊断公司之间加强合作以开发个人化治疗和诊断测试也支持了这一领域的成长。医院和诊所将作为这些公司的资料储存库，从这些机构收集真实世界的资料，以开发先进的精准解决方案。预计这种高成长态势将在预测期内持续下去。

预计亚太地区精准诊断市场将在预测期内达到最高成长率。这种高成长可归因于该地区慢性病、癌症和遗传疾病病例的增加，从而刺激了对精准诊断解决方案的需求。这一增长得益于中国、印度和日本等国家对医疗保健基础设施的投资，这些国家获得了更多先进的诊断技术。此外，次世代定序(NGS)、人工智慧和机器学习等技术的采用正在推动该领域的创新。政府措施和医疗保险的改善也有助于扩大精准诊断的机会。此外，政府机构对生命科学研发的支持和资助也帮助亚太地区精准诊断市场快速成长。

本报告研究了全球精准诊断和精准医疗市场，并按类型、适应症、产品、最终用户、区域趋势和公司概况进行细分。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章 市场概况

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/中断
  • 定价分析
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 管道分析
  • 诊断产品分析
  • 投资/资金筹措活动
  • 技术分析
  • 专利分析
  • 贸易分析
  • 2025-2026 年重要会议与活动
  • 监管状态
  • 波特五力分析
  • 主要相关人员和采购标准
  • 人工智慧/产生人工智慧对精准诊断和精准医疗市场的影响

第六章 精准诊断市场（依类型）

  • 介绍
  • 基因检测
  • DTC 检查
  • 其他的

第七章 精准诊断市场（依适应症划分）

  • 介绍
  • 肿瘤学
  • 神经病学
  • 免疫学
  • 其他的

第 8 章 精密诊断市场（依最终用户划分）

  • 介绍
  • 临床实验室
  • 医院
  • 居家医疗

第 9 章 精准医疗市场（依产品分类）

  • 介绍
  • 单株抗体
  • 抑制剂
  • 细胞和基因治疗
  • 抗病毒和抗逆转录病毒药物
  • 其他的

第 10 章 精准医疗市场（依适应症划分）

  • 介绍
  • 肿瘤学
  • 罕见疾病
  • 感染疾病
  • 血液系统疾病
  • 其他的

第 11 章 精准医疗市场（依最终用户划分）

  • 介绍
  • 医院和诊所
  • 居家医疗

12. 精准诊断及精准医疗市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 中东和非洲宏观经济展望

第十三章 竞争格局

  • 概述
  • 主要参与企业的策略/优势，2021-2024 年
    • 精准诊断市场
    • 精准医疗市场
  • 2021-2023 年收益分析
  • 2023 年市场占有率分析
  • 公司估值矩阵：主要参与企业，2023 年
  • 公司估值矩阵：Start-Ups/中小企业，2023 年
  • 公司估值与财务指标
  • 品牌/产品比较
  • 精准诊断市场：竞争格局
  • 精准医疗市场：竞争格局

第十四章 公司简介

  • 主要参与企业
    • F. HOFFMANN-LA ROCHE LTD（DIAGNOSTICS）
    • ABBOTT
    • AGILENT TECHNOLOGIES, INC.
    • GUARDANT HEALTH
    • EXACT SCIENCES CORPORATION
    • QIAGEN
    • MYRIAD GENETICS, INC.
    • NATERA, INC.
    • ILLUMINA, INC.
    • THERMO FISHER SCIENTIFIC INC.
    • DANAHER
    • 23ANDME, INC.
    • MERCK & CO., INC.
    • GILEAD SCIENCES, INC.
    • F. HOFFMANN-LA ROCHE LTD（MEDICINE）
    • BRISTOL-MYERS SQUIBB COMPANY
    • NOVARTIS AG
    • ASTRAZENECA
    • ABBVIE INC.
    • LILLY
    • PFIZER INC.
    • SAREPTA THERAPEUTICS, INC.
    • VERTEX PHARMACEUTICALS INCORPORATED
    • GSK PLC.
  • 其他公司
    • SANOFI
    • JOHNSON & JOHNSON SERVICES, INC.
    • AMGEN INC.
    • MERCK KGAA
    • ALNYLAM PHARMACEUTICALS, INC.
    • INCYTE
    • ARUP LABORATORIES
    • DEVYSER
    • DIASORIN SPA
    • TEMPUS
    • PILLAR BIOSCIENCES INC.
    • INVIVOSCRIBE, INC.
    • NEUROCODE
    • C2N DIAGNOSTICS
    • TRINITY BIOTECH
    • AMOY DIAGNOSTICS CO., LTD.

第十五章 附录

Product Code: BT 8776

The global Precision Diagnostics and Medicine market is projected to reach USD 246.66 billion in 2029 from USD 145.53 billion by 2024, at a CAGR of 11.1% during the forecast period. Factors such as the ongoing integration of advanced technologies such as artificial intelligence and machine learning to enhance precision medicine development, supported by the rising collaboration and investments by major pharmaceutical and diagnostics companies to develop better precision medicine solutions are supporting the growth of the market. Moreover, the expanding focus of these companies to develop precision therapies and diagnostic tests for multiple diseases such as neurodegenerative and autoimmune diseases highlight the growing importance of precision medicine in healthcare. Additionally, the increasing awareness of patients regarding their health is supporting the adoption of wearable medical devices and direct-to-consumer precision diagnostic tests offering growth opportunities to players in this market. However, the high cost of precision healthcare and challenges associated with the integration and management of big data in healthcare are expected to restrain the growth of this market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Diagnostic Solution Type, Diagnostic Solution Indication, Diagnostic Solution End Users, Therapeutic Solution Products
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The monoclonal antibodies segment registered the highest growth rate in the precision medicine market, by products, during the forecast period"

In 2023, the monoclonal antibodies segment registered the highest growth rate within the precision medicine market by products. Factors such as the increasing collaborations to develop advanced monoclonal antibodies and advancements in antibody engineering technologies are attributed to the growth of this segment. Additionally, these modalities offer various advantages over traditional drugs such as high specificity, low toxicity, and longer-lasting effects among others increasing the adoption of these drug modalities for the treatment of cancer, autoimmune, and infectious diseases supporting the growth of this segment.

"The hospitals and clinics end user segment registered the highest growth rate and largest market share in the precision medicine market, by end user, during the forecast period"

The hospitals and clinic end users registered the highest growth rate within the precision medicine market by end user segment during the forecast period. Factors such as the growing demand for personalized treatments and the ability of hospitals and clinics to offer personalized therapies in a controlled environment can be attributed to the large share of this end user segment. Moreover, the rising collaborations between hospitals and pharmaceutical and diagnostic companies to develop personalized therapies and diagnostic tests support the growth of this segment. Hospitals and clinics act as data reservoirs for these companies which gather real-world data from these institutions for the development of advanced precision solutions. This high growth is projected to continue during the forecast period.

"Asia Pacific: The fastest growing region in the Precision Diagnostics market"

The precision diagnostics market of Asia Pacific is projected to register the highest growth rate during the forecast period. This high growth is attributed to the rising cases of chronic diseases, cancer, and genetic disorders in this region leading to a growing demand for precision diagnostics solutions. This growth is supported by investments in healthcare infrastructure across countries like China, India, and Japan, enhancing access to advanced diagnostic technologies. Additionally, the adoption of technologies like next-generation sequencing (NGS), artificial intelligence, and machine learning is driving innovations in the field. Government initiatives and improved healthcare coverage also contribute to expanding access to precision diagnostics. Moreover, the support and funding from government organizations for life sciences research and development also support the rapid growth of the Asia Pacific precision diagnostics market.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 44%, Tier 2 - 32%, and Tier 3 - 24%
  • By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%

List of Companies Profiled in the Report:

  • Merck & Co., Inc. (US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Agilent Technologies, Inc. (US)
  • Thermo Fisher Scientific Inc. (US)
  • Myriad Genetics, Inc. (US)
  • Guardant Health (US)
  • Abbott (US)
  • Natera Inc. (US)
  • Illumina, Inc. (US)
  • Danaher (US)
  • Exact Sciences Corporation (US)
  • Qiagen (Netherlands)
  • 23andME, INC. (US)
  • ARUP Laboratories. (US)
  • Devyser (Sweden)
  • Diasorin S.P.A. (Italy)
  • Tempus (US)
  • Pillar Biosciences Inc. (US)
  • Invivoscribe, Inc. (US)
  • NeuroCode (US)
  • C2N Diagnostics (US)
  • Trinity Biotech Plc. (Ireland)
  • Amoy Diagnostics Co., Ltd. (China)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb Company (US)
  • Gilead Sciences, Inc. (US)
  • AstraZeneca (UK)
  • AbbVie Inc. (US)
  • Eli Lilly and Company. (US)
  • Pfizer Inc. (US), GSK plc. (UK)
  • Sanofi (France)
  • Johnson & Johnson Services, Inc. (US)
  • Vertex Pharmaceuticals Incorporated (US)
  • Amgen Inc. (US)
  • Merck KGaA (Germany)
  • Sarepta Therapeutics, Inc. (US).

Research Coverage:

This report provides a detailed picture of the global Precision Diagnostics and Medicine Market. It aims to estimate the size and future growth potential of the market across different segments such as the precision diagnostics market (type, indication, and end user) and precision medicine market (product, indication, and end user) region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the precision diagnostics and medicine market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the precision diagnostics and medicine market. Competitive analysis of upcoming startups in the precision diagnostics and medicine market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall precision diagnostics and medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing Integration Of AI And ML To Improve Precision Diagnostics And Therapy Development, Rising Collaborations Between Pharmaceutical And Diagnostics Company To Enhance Precision Healthcare and Rise in direct-to-consumer testing), restraints (High costs of precision healthcare and Slow Pace Of Reimbursement For Precision Diagnostics), opportunities (Expanding The Application Of Precision Diagnostics From Oncology and Integration of wearable devices to enhance precision healthcare), and challenges (Challenges in Regulatory Approval for Diagnostics and Big Data Management and Integration) influencing the growth of the precision diagnostics and medicine market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches and approvals in the precision diagnostics and medicine market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the precision diagnostics and medicine market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the precision diagnostics and medicine market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players in precision diagnostics market like- F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Guardant Health (US), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US) among others and precision medicine market like- Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US) Gilead Sciences, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Novartis AG (Switzerland), among others.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION METHODOLOGY
    • 2.2.1 PRECISION DIAGNOSTICS MARKET
    • 2.2.2 PRECISION MEDICINE MARKET
    • 2.2.3 INSIGHTS FROM PRIMARY SOURCES
  • 2.3 TOP-DOWN APPROACH
    • 2.3.1 PRECISION DIAGNOSTICS MARKET
    • 2.3.2 PRECISION MEDICINE MARKET
  • 2.4 GROWTH FORECAST MODEL
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6 RESEARCH ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW
  • 4.2 PRECISION MEDICINE MARKET OVERVIEW
  • 4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023
  • 4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029
  • 4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023
  • 4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023
  • 4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029
  • 4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies
      • 5.2.1.2 Rise in direct-to-consumer testing
      • 5.2.1.3 Growing integration of artificial intelligence and machine learning
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of precision healthcare
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Expanding applications of precision healthcare
      • 5.2.3.2 Growing adoption of wearable devices
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complex regulatory approval landscape
      • 5.2.4.2 Big data management and integration issues
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • 5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER
    • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 VALUE CHAIN ANALYSIS
    • 5.5.1 PRECISION DIAGNOSTICS MARKET
    • 5.5.2 PRECISION MEDICINE MARKET
  • 5.6 SUPPLY CHAIN ANALYSIS
    • 5.6.1 PRECISION DIAGNOSTICS MARKET
    • 5.6.2 PRECISION MEDICINE MARKET
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 PIPELINE ANALYSIS
  • 5.9 DIAGNOSTIC PRODUCT ANALYSIS
  • 5.10 INVESTMENT/FUNDING ACTIVITY
  • 5.11 TECHNOLOGY ANALYSIS
    • 5.11.1 KEY TECHNOLOGIES
      • 5.11.1.1 Next-generation sequencing
      • 5.11.1.2 Immunohistochemistry
      • 5.11.1.3 Liquid biopsy
    • 5.11.2 COMPLEMENTARY TECHNOLOGIES
      • 5.11.2.1 Single-cell analysis
      • 5.11.2.2 AI and ML integration
    • 5.11.3 ADJACENT TECHNOLOGIES
      • 5.11.3.1 Theranostics
      • 5.11.3.2 Imaging technologies
  • 5.12 PATENT ANALYSIS
  • 5.13 TRADE ANALYSIS
    • 5.13.1 IMPORT DATA
    • 5.13.2 EXPORT DATA
  • 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.15 REGULATORY LANDSCAPE
    • 5.15.1 REGULATORY ANALYSIS
      • 5.15.1.1 North America
      • 5.15.1.2 Europe
      • 5.15.1.3 Asia Pacific
      • 5.15.1.4 Rest of the World
    • 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.16 PORTER'S FIVE FORCES ANALYSIS
    • 5.16.1 PRECISION DIAGNOSTICS MARKET
      • 5.16.1.1 Threat of new entrants
      • 5.16.1.2 Threat of substitutes
      • 5.16.1.3 Bargaining power of buyers
      • 5.16.1.4 Bargaining power of suppliers
      • 5.16.1.5 Intensity of competitive rivalry
    • 5.16.2 PRECISION MEDICINE MARKET
      • 5.16.2.1 Threat of new entrants
      • 5.16.2.2 Threat of substitutes
      • 5.16.2.3 Bargaining power of buyers
      • 5.16.2.4 Bargaining power of suppliers
      • 5.16.2.5 Intensity of competitive rivalry
  • 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.17.2 BUYING CRITERIA
  • 5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET
    • 5.18.1 INTRODUCTION
    • 5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES
    • 5.18.3 AI USE CASES
    • 5.18.4 KEY COMPANIES IMPLEMENTING AI
    • 5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND MEDICINE ECOSYSTEM

6 PRECISION DIAGNOSTICS MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 GENETIC TESTING
    • 6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH
  • 6.3 DTC TESTING
    • 6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO ENCOURAGE GROWTH
  • 6.4 OTHER TYPES

7 PRECISION DIAGNOSTICS MARKET, BY INDICATION

  • 7.1 INTRODUCTION
  • 7.2 ONCOLOGY
    • 7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH
  • 7.3 NEUROLOGY
    • 7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET
  • 7.4 IMMUNOLOGY
    • 7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET
  • 7.5 OTHER DIAGNOSTIC INDICATIONS

8 PRECISION DIAGNOSTICS MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 CLINICAL LABORATORIES
    • 8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH
  • 8.3 HOSPITALS
    • 8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET
  • 8.4 HOME CARE SETTINGS
    • 8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH

9 PRECISION MEDICINE MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 MONOCLONAL ANTIBODIES
    • 9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH
  • 9.3 INHIBITOR DRUGS
    • 9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH
  • 9.4 CELL & GENE THERAPIES
    • 9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET
  • 9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS
    • 9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH
  • 9.6 OTHER PRODUCTS

10 PRECISION MEDICINE MARKET, BY INDICATION

  • 10.1 INTRODUCTION
  • 10.2 ONCOLOGY
    • 10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET
  • 10.3 RARE DISEASES
    • 10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH
  • 10.4 INFECTIOUS DISEASES
    • 10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET
  • 10.5 HEMATOLOGICAL DISORDERS
    • 10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH
  • 10.6 OTHER MEDICINE INDICATIONS

11 PRECISION MEDICINE MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS & CLINICS
    • 11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET
  • 11.3 HOME CARE SETTINGS
    • 11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH

12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth
    • 12.2.3 CANADA
      • 12.2.3.1 Growing cancer burden to support growth
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market
    • 12.3.3 UK
      • 12.3.3.1 Favorable government support to expedite growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Growing preference for personalized medicine to fuel market
    • 12.3.5 ITALY
      • 12.3.5.1 Rise in genomics research and diagnostic testing to foster growth.
    • 12.3.6 SPAIN
      • 12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Growing regulatory approvals for precision medicines to boost market
    • 12.4.3 JAPAN
      • 12.4.3.1 Increasing availability of health insurance to encourage growth
    • 12.4.4 INDIA
      • 12.4.4.1 Rising burden of chronic diseases to promote growth
    • 12.4.5 AUSTRALIA
      • 12.4.5.1 Booming research & development investments to spur growth
    • 12.4.6 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market
    • 12.5.3 MEXICO
      • 12.5.3.1 Booming biopharmaceutical sector to contribute to growth
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024
    • 13.2.1 PRECISION DIAGNOSTICS MARKET
    • 13.2.2 PRECISION MEDICINE MARKET
  • 13.3 REVENUE ANALYSIS, 2021-2023
    • 13.3.1 PRECISION DIAGNOSTICS MARKET
    • 13.3.2 PRECISION MEDICINE MARKET
  • 13.4 MARKET SHARE ANALYSIS, 2023
    • 13.4.1 PRECISION DIAGNOSTICS MARKET
    • 13.4.2 PRECISION MEDICINE MARKET
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 PRECISION DIAGNOSTICS MARKET
      • 13.5.1.1 Stars
      • 13.5.1.2 Emerging leaders
      • 13.5.1.3 Pervasive players
      • 13.5.1.4 Participants
      • 13.5.1.5 Company footprint: Key players, 2023
        • 13.5.1.5.1 Company footprint
        • 13.5.1.5.2 Region footprint
        • 13.5.1.5.3 Type footprint
        • 13.5.1.5.4 Indication footprint
    • 13.5.2 PRECISION MEDICINE MARKET
      • 13.5.2.1 Stars
      • 13.5.2.2 Emerging leaders
      • 13.5.2.3 Pervasive players
      • 13.5.2.4 Participants
      • 13.5.2.5 Company footprint: Key players, 2023
        • 13.5.2.5.1 Company footprint
        • 13.5.2.5.2 Region footprint
        • 13.5.2.5.3 Product footprint
        • 13.5.2.5.4 Indication footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 13.6.1 PRECISION DIAGNOSTICS MARKET
      • 13.6.1.1 Progressive companies
      • 13.6.1.2 Responsive companies
      • 13.6.1.3 Dynamic companies
      • 13.6.1.4 Starting blocks
      • 13.6.1.5 Competitive benchmarking
        • 13.6.1.5.1 Detailed list of key startups/SMES
        • 13.6.1.5.2 Competitive benchmarking of startups/SMEs
    • 13.6.2 PRECISION MEDICINE MARKET
      • 13.6.2.1 Progressive companies
      • 13.6.2.2 Responsive companies
      • 13.6.2.3 Dynamic companies
      • 13.6.2.4 Starting blocks
      • 13.6.2.5 Competitive benchmarking
        • 13.6.2.5.1 Detailed list of key startups/SMES
        • 13.6.2.5.2 Competitive benchmarking of startups/SMEs
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 13.7.1 PRECISION DIAGNOSTICS MARKET
    • 13.7.2 PRECISION MEDICINE MARKET
  • 13.8 BRAND/PRODUCT COMPARISON
  • 13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS
  • 13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO
    • 13.10.1 PRODUCT LAUNCHES AND APPROVALS
    • 13.10.2 DEALS
    • 13.10.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches and approvals
        • 14.1.1.3.2 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 ABBOTT
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 AGILENT TECHNOLOGIES, INC.
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches and approvals
        • 14.1.3.3.2 Deals
        • 14.1.3.3.3 Expansions
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 GUARDANT HEALTH
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches and approvals
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 EXACT SCIENCES CORPORATION
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches and approvals
        • 14.1.5.3.2 Deals
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 QIAGEN
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches and approvals
        • 14.1.6.3.2 Deals
    • 14.1.7 MYRIAD GENETICS, INC.
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Product launches and approvals
        • 14.1.7.3.2 Deals
        • 14.1.7.3.3 Other developments
    • 14.1.8 NATERA, INC.
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches and approvals
        • 14.1.8.3.2 Deals
    • 14.1.9 ILLUMINA, INC.
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Product launches and approvals
        • 14.1.9.3.2 Deals
    • 14.1.10 THERMO FISHER SCIENTIFIC INC.
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches and approvals
        • 14.1.10.3.2 Deals
    • 14.1.11 DANAHER
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Product launches and approvals
        • 14.1.11.3.2 Deals
    • 14.1.12 23ANDME, INC.
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Deals
    • 14.1.13 MERCK & CO., INC.
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Product launches and approvals
        • 14.1.13.3.2 Deals
    • 14.1.14 GILEAD SCIENCES, INC.
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Product launches and approvals
        • 14.1.14.3.2 Deals
    • 14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE)
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products offered
      • 14.1.15.3 Recent developments
        • 14.1.15.3.1 Product launches and approvals
    • 14.1.16 BRISTOL-MYERS SQUIBB COMPANY
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products offered
      • 14.1.16.3 Recent developments
        • 14.1.16.3.1 Product launches and approvals
        • 14.1.16.3.2 Deals
    • 14.1.17 NOVARTIS AG
      • 14.1.17.1 Business overview
      • 14.1.17.2 Products offered
      • 14.1.17.3 Recent developments
        • 14.1.17.3.1 Product launches and approvals
        • 14.1.17.3.2 Deals
    • 14.1.18 ASTRAZENECA
      • 14.1.18.1 Business overview
      • 14.1.18.2 Products offered
      • 14.1.18.3 Recent developments
        • 14.1.18.3.1 Product launches and approvals
        • 14.1.18.3.2 Deals
    • 14.1.19 ABBVIE INC.
      • 14.1.19.1 Business overview
      • 14.1.19.2 Products offered
      • 14.1.19.3 Recent developments
        • 14.1.19.3.1 Product launches and approvals
        • 14.1.19.3.2 Deals
        • 14.1.19.3.3 Expansions
    • 14.1.20 LILLY
      • 14.1.20.1 Business overview
      • 14.1.20.2 Products offered
      • 14.1.20.3 Recent developments
        • 14.1.20.3.1 Product launches and approvals
        • 14.1.20.3.2 Deals
    • 14.1.21 PFIZER INC.
      • 14.1.21.1 Business overview
      • 14.1.21.2 Products offered
      • 14.1.21.3 Recent developments
        • 14.1.21.3.1 Product launches and approvals
        • 14.1.21.3.2 Deals
    • 14.1.22 SAREPTA THERAPEUTICS, INC.
      • 14.1.22.1 Business overview
      • 14.1.22.2 Products offered
      • 14.1.22.3 Recent developments
        • 14.1.22.3.1 Product launches and approvals
        • 14.1.22.3.2 Deals
    • 14.1.23 VERTEX PHARMACEUTICALS INCORPORATED
      • 14.1.23.1 Business overview
      • 14.1.23.2 Products offered
      • 14.1.23.3 Recent developments
        • 14.1.23.3.1 Product launches and approvals
        • 14.1.23.3.2 Deals
    • 14.1.24 GSK PLC.
      • 14.1.24.1 Business overview
      • 14.1.24.2 Products offered
      • 14.1.24.3 Recent developments
        • 14.1.24.3.1 Product launches and approvals
        • 14.1.24.3.2 Deals
  • 14.2 OTHER PLAYERS
    • 14.2.1 SANOFI
    • 14.2.2 JOHNSON & JOHNSON SERVICES, INC.
    • 14.2.3 AMGEN INC.
    • 14.2.4 MERCK KGAA
    • 14.2.5 ALNYLAM PHARMACEUTICALS, INC.
    • 14.2.6 INCYTE
    • 14.2.7 ARUP LABORATORIES
    • 14.2.8 DEVYSER
    • 14.2.9 DIASORIN S.P.A.
    • 14.2.10 TEMPUS
    • 14.2.11 PILLAR BIOSCIENCES INC.
    • 14.2.12 INVIVOSCRIBE, INC.
    • 14.2.13 NEUROCODE
    • 14.2.14 C2N DIAGNOSTICS
    • 14.2.15 TRINITY BIOTECH
    • 14.2.16 AMOY DIAGNOSTICS CO., LTD.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RISK ASSESSMENT
  • TABLE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 4 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS, BY KEY PLAYER, 2021-2023 (USD)
  • TABLE 5 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER, 2021-2023 (USD)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY REGION, 2021-2023 (USD)
  • TABLE 7 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 8 PRECISION MEDICINE PRODUCTS IN CLINICAL PIPELINE, 2025-2029
  • TABLE 9 PRECISION DIAGNOSTIC TESTS APPROVED BY FDA
  • TABLE 10 PRECISION DIAGNOSTIC PRODUCTS ANALYSIS
  • TABLE 11 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
  • TABLE 12 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2019-2024
  • TABLE 13 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (USD THOUSAND)
  • TABLE 14 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (TONS)
  • TABLE 15 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (USD THOUSAND)
  • TABLE 16 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (TONS)
  • TABLE 17 PRECISION DIAGNOSTICS AND MEDICINE MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 PRECISION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 24 PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE
  • TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT
  • TABLE 27 BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER
  • TABLE 28 BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER
  • TABLE 29 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 30 PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 31 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 32 EUROPE: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 33 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 34 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 35 PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 36 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 37 EUROPE: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 38 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 39 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 40 PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 41 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 42 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 43 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 44 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 45 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 46 PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 47 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 48 EUROPE: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 49 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 50 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 51 PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 52 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 53 EUROPE: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 54 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 55 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 56 PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 57 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 58 EUROPE: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 59 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 60 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 61 PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 62 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 63 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 64 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 65 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 66 PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 67 PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 68 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 69 EUROPE: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 70 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 71 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 72 PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 73 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 74 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 75 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 76 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 77 PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 78 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 79 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 80 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 81 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 82 PRECISION MEDICINE MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 83 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 84 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 85 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 86 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 87 LATIN AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 88 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 89 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 90 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 91 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 92 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 93 PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 94 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 95 EUROPE: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 96 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 97 LATIN AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 98 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 99 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 100 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 102 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 103 PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 104 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 105 EUROPE: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 106 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 107 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 108 PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 109 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 110 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 111 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 112 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 113 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 114 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 115 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 116 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 117 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 118 LATIN AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 119 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 120 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 121 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 122 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 123 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 124 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 125 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 126 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 127 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 128 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 129 PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 130 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 131 EUROPE: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 132 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 133 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 134 PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 135 PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 141 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 145 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 146 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 147 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 148 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 149 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 150 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 151 NORTH AMERICA: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
  • TABLE 152 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 153 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 155 US: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 156 US: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 157 US: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 158 US: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 159 US: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 160 US: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
  • TABLE 161 CANADA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 162 CANADA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 163 CANADA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 164 CANADA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 165 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 166 CANADA: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
  • TABLE 167 EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 168 EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 169 EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 170 EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 171 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 172 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 173 EUROPE: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 174 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 175 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 176 GERMANY: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 177 GERMANY: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 178 GERMANY: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 179 GERMANY: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 180 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 181 GERMANY: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
  • TABLE 182 UK: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 183 UK: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 184 UK: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 185 UK: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 186 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 187 UK: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 188 FRANCE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 189 FRANCE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 190 FRANCE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 191 FRANCE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 192 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 193 FRANCE: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
  • TABLE 194 ITALY: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 195 ITALY: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 196 ITALY: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 197 ITALY: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 198 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 199 ITALY: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
  • TABLE 200 SPAIN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 201 SPAIN: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 202 SPAIN: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 203 SPAIN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 204 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 205 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 206 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 207 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 208 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 209 REST OF EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 210 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 211 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 212 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 213 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 214 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 215 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 216 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 217 ASIA PACIFIC: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
  • TABLE 218 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 219 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 220 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 221 CHINA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 222 CHINA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 223 CHINA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 224 CHINA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 225 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 226 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 227 JAPAN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 228 JAPAN: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 229 JAPAN: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 230 JAPAN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 231 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 232 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 233 INDIA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 234 INDIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 235 INDIA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 236 INDIA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 237 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 238 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 239 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 240 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 241 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 242 AUSTRALIA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 243 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 244 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 245 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 246 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 247 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 248 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 249 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 250 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 251 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 252 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 253 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 254 LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 255 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 256 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 257 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 258 LATIN AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 259 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 260 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 261 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 262 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 263 BRAZIL: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 264 BRAZIL: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 265 BRAZIL: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 266 MEXICO: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 267 MEXICO: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 268 MEXICO: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 269 MEXICO: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 270 MEXICO: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 271 MEXICO: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 272 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 273 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 274 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 275 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 276 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 277 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 278 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 279 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 281 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
  • TABLE 282 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
  • TABLE 283 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 284 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 285 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION DIAGNOSTICS MARKET, JANUARY 2021-NOVEMBER 2024
  • TABLE 286 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION MEDICINE MARKET, JANUARY 2021-NOVEMBER 2024
  • TABLE 287 PRECISION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 288 PRECISION MEDICINE MARKET: DEGREE OF COMPETITION
  • TABLE 289 PRECISION DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 290 PRECISION DIAGNOSTICS MARKET: TYPE FOOTPRINT
  • TABLE 291 PRECISION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
  • TABLE 292 PRECISION MEDICINE MARKET: REGION FOOTPRINT
  • TABLE 293 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT
  • TABLE 294 PRECISION MEDICINE MARKET: INDICATION FOOTPRINT
  • TABLE 295 PRECISION DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 296 PRECISION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 297 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 298 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 299 PRECISION DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 300 PRECISION DIAGNOSTICS MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 301 PRECISION DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 302 PRECISION MEDICINE MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 303 PRECISION MEDICINE MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 304 PRECISION MEDICINE: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 305 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY OVERVIEW
  • TABLE 306 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCTS OFFERED
  • TABLE 307 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 308 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 309 ABBOTT: COMPANY OVERVIEW
  • TABLE 310 ABBOTT: PRODUCTS OFFERED
  • TABLE 311 ABBOTT: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 312 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 313 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 314 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 315 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 316 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 317 GUARDANT HEALTH: COMPANY OVERVIEW
  • TABLE 318 GUARDANT HEALTH: PRODUCTS OFFERED
  • TABLE 319 GUARDANT HEALTH: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 320 GUARDANT HEALTH: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 321 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
  • TABLE 322 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED
  • TABLE 323 EXACT SCIENCES CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 324 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 325 QIAGEN: COMPANY OVERVIEW
  • TABLE 326 QIAGEN: PRODUCTS OFFERED
  • TABLE 327 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 328 QIAGEN: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 329 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 330 MYRIAD GENETICS, INC.: PRODUCTS OFFERED
  • TABLE 331 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 332 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 333 MYRIAD GENETICS, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 334 NATERA, INC.: COMPANY OVERVIEW
  • TABLE 335 NATERA, INC.: PRODUCTS OFFERED
  • TABLE 336 NATERA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 337 NATERA, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 338 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 339 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 340 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 341 ILLUMINA, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 342 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 343 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 344 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 345 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 346 DANAHER: COMPANY OVERVIEW
  • TABLE 347 DANAHER: PRODUCTS OFFERED
  • TABLE 348 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 349 DANAHER: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 350 23ANDME, INC.: COMPANY OVERVIEW
  • TABLE 351 23ANDME, INC.: PRODUCTS OFFERED
  • TABLE 352 23ANDME, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 353 MERCK & CO., INC.: COMPANY OVERVIEW
  • TABLE 354 MERCK & CO., INC.: PRODUCTS OFFERED
  • TABLE 355 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 356 MERCK & CO., INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 357 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 358 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 359 GILEAD SCIENCES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 360 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 361 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY OVERVIEW
  • TABLE 362 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCTS OFFERED
  • TABLE 363 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 364 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
  • TABLE 365 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
  • TABLE 366 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 367 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 368 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 369 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 370 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 371 NOVARTIS AG: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 372 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 373 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 374 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 375 ASTRAZENECA: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 376 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 377 ABBVIE INC.: PRODUCTS OFFERED
  • TABLE 378 ABBVIE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 379 ABBVIE INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 380 ABBVIE INC.: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 381 LILLY: COMPANY OVERVIEW
  • TABLE 382 LILLY: PRODUCTS OFFERED
  • TABLE 383 LILLY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 384 LILLY: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 385 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 386 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 387 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 388 PFIZER INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 389 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 390 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
  • TABLE 391 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 392 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 393 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY OVERVIEW
  • TABLE 394 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCTS OFFERED
  • TABLE 395 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 396 VERTEX PHARMACEUTICALS INCORPORATED: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 397 GSK PLC.: COMPANY OVERVIEW
  • TABLE 398 GSK PLC.: PRODUCTS OFFERED
  • TABLE 399 GSK PLC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 400 GSK PLC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 401 SANOFI: COMPANY OVERVIEW
  • TABLE 402 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 403 AMGEN INC.: COMPANY OVERVIEW
  • TABLE 404 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 405 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 406 INCYTE: COMPANY OVERVIEW
  • TABLE 407 ARUP LABORATORIES: COMPANY OVERVIEW
  • TABLE 408 DEVYSER: COMPANY OVERVIEW
  • TABLE 409 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 410 TEMPUS: COMPANY OVERVIEW
  • TABLE 411 PILLAR BIOSCIENCES INC.: COMPANY OVERVIEW
  • TABLE 412 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
  • TABLE 413 NEUROCODE: COMPANY OVERVIEW
  • TABLE 414 C2N DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 415 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 416 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET SEGMENTATION
  • FIGURE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RESEARCH DESIGN
  • FIGURE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
  • FIGURE 5 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE ANALYSIS, 2023
  • FIGURE 7 PRECISION MEDICINE MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 PRECISION MEDICINE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 9 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS, 2023
  • FIGURE 10 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 11 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 12 PRECISION MEDICINE MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 13 PRECISION DIAGNOSTICS MARKET: CAGR PROJECTIONS, 2024-2029
  • FIGURE 14 PRECISION MEDICINE MARKET: CAGR PROJECTIONS, 2024-2029
  • FIGURE 15 PRECISION DIAGNOSTICS AND MEDICINE MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
  • FIGURE 16 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DATA TRIANGULATION
  • FIGURE 17 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
  • FIGURE 18 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION)
  • FIGURE 19 PRECISION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
  • FIGURE 20 PRECISION MEDICINE MARKET, BY PRODUCT, 2024 VS. 2029 (USD BILLION)
  • FIGURE 21 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION)
  • FIGURE 22 PRECISION MEDICINE MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
  • FIGURE 23 GEOGRAPHICAL SNAPSHOT OF PRECISION DIAGNOSTICS MARKET, 2024-2029
  • FIGURE 24 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET, 2024-2029
  • FIGURE 25 INCREASING DEMAND FOR QUICK AND ACCURATE DIAGNOSTIC TESTS TO DRIVE PRECISION DIAGNOSTICS MARKET
  • FIGURE 26 INCREASING NUMBER OF REGULATORY APPROVALS FOR PERSONALIZED MEDICINES TO DRIVE PRECISION MEDICINE MARKET
  • FIGURE 27 GENETIC TESTING SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF PRECISION DIAGNOSTICS MARKET IN 2023
  • FIGURE 28 ONCOLOGY SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 29 HOME CARE SETTINGS MARKET COMMANDED HIGHEST SHARE IN 2023
  • FIGURE 30 MONOCLONAL ANTIBODIES AND US LED NORTH AMERICAN PRECISION MEDICINE MARKET IN 2023
  • FIGURE 31 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 32 JAPAN TO REGISTER HIGHEST GROWTH IN PRECISION DIAGNOSTICS MARKET DURING FORECAST PERIOD
  • FIGURE 33 GERMANY TO REGISTER HIGHEST GROWTH IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD
  • FIGURE 34 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 35 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PRECISION DIAGNOSTICS AND MEDICINE MARKET
  • FIGURE 36 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS, BY KEY PLAYER, 2021-2023 (USD)
  • FIGURE 37 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER, 2021-2023 (USD)
  • FIGURE 38 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY REGION, 2021-2023 (USD)
  • FIGURE 39 PRECISION DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 40 PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 41 PRECISION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 42 PRECISION MEDICINE MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 43 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 44 PRECISION DIAGNOSTICS AND MEDICINE MARKET: PATENT ANALYSIS, JANUARY 2014-NOVEMBER 2024
  • FIGURE 45 PRECISION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 46 PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 47 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE
  • FIGURE 48 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT
  • FIGURE 49 KEY BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER
  • FIGURE 50 KEY BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER
  • FIGURE 51 NORTH AMERICA: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT
  • FIGURE 52 EUROPE: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT
  • FIGURE 53 PRECISION DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
  • FIGURE 54 PRECISION MEDICINE MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
  • FIGURE 55 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 56 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 57 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 58 PRECISION DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 59 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 60 PRECISION MEDICINE MARKET: COMPANY FOOTPRINT
  • FIGURE 61 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 62 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 63 PRECISION DIAGNOSTICS MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 64 PRECISION DIAGNOSTICS MARKET: EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 65 PRECISION MEDICINE MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 66 PRECISION MEDICINE MARKET: EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 67 PRECISION DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 68 PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 69 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY SNAPSHOT (2023)
  • FIGURE 70 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 71 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 72 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
  • FIGURE 73 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 74 QIAGEN: COMPANY SNAPSHOT (2023)
  • FIGURE 75 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 76 NATERA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 77 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 78 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 79 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 80 23ANDME, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 81 MERCK & CO., INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 82 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 83 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY SNAPSHOT (2023)
  • FIGURE 84 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 85 NOVARTIS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 86 ASTRAZENECA: COMPANY SNAPSHOT (2023)
  • FIGURE 87 ABBVIE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 88 LILLY: COMPANY SNAPSHOT (2023)
  • FIGURE 89 PFIZER INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 90 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 91 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT (2023)
  • FIGURE 92 GSK PLC.: COMPANY SNAPSHOT (2023)